8-K: Oragenics Appoints Dr. William Frank Peacock as Chief Clinical Officer to Lead Concussion Trial

Oragenics has appointed Dr. William Frank Peacock as Chief Clinical Officer to oversee the upcoming Phase II clinical trial for their concussion treatment, ONP-002.

Summary

• Oragenics, Inc. has appointed Dr. William Frank Peacock as its Chief Clinical Officer.
• Dr. Peacock will lead the company's Phase II clinical trial for ONP-002, a drug-device combination for treating mild traumatic brain injury (mTBI), also known as concussion.
• The Phase II trial will focus on the time to first dose, the relationship between drug application and blood biomarker levels, and the evaluation of patient symptom severity.
• ONP-002 is designed to target the brain through intranasal delivery.
• A previous 40-patient Phase I study showed the drug to be safe and well-tolerated.
• Dr. Peacock is a renowned expert in emergency medicine and concussion research, with over 30 years of experience.
• Oragenics is working with Avance Clinical, a CRO, for the Phase II trial.
• There are an estimated 69 million concussions reported annually worldwide.

Sentiment

Score: 8

Explanation: The appointment of a highly qualified Chief Clinical Officer and the progression to a Phase II trial are positive developments. The company is addressing a significant unmet medical need with a novel approach.

Positives

• The appointment of Dr. William Frank Peacock as Chief Clinical Officer brings significant expertise in emergency medicine and concussion research to Oragenics.
• The Phase I study demonstrated that ONP-002 is safe and well-tolerated in humans.
• The Phase II trial is designed to gather crucial data on the drug's effectiveness, including time to first dose, biomarker levels, and symptom severity.
• ONP-002's intranasal delivery method has shown enhanced brain exposure and metabolism in animal models.
• The collaboration with Avance Clinical, a CRO, should help streamline the Phase II trial process.

Risks

• The company's ability to advance the development of its product candidates, including the neurology assets, under the timelines and in accord with the milestones it projects is a risk.
• The company's ability to raise capital and obtain funding, non-dilutive or otherwise, for the development of its product candidates is a risk.
• The regulatory application process, research and development stages, and future clinical data and analysis relating to its product candidates, including any meetings, decisions by regulatory authorities, such as the FDA and investigational review boards, whether favorable or unfavorable, is a risk.
• The company's ability to obtain, maintain and enforce necessary patent and other intellectual property protection is a risk.
• The nature of competition and development relating to concussion treatments is a risk.
• The company's expectations as to the outcome of preclinical studies and clinical trials and the potential benefits, activity, effectiveness and safety of its product candidates including as to administration, transmission, manufacturing, storage and distribution is a risk.
• General economic and market conditions and risks are a risk.

Future Outlook

The company is focused on advancing its Phase II clinical trial for ONP-002 and is working with Avance Clinical to achieve this. The company is also developing other treatments for neurological disorders and infectious diseases.

Management Comments

• Dr. Peacock stated he is excited to join Oragenics at such an important and pivotal time in the company's clinical program and is looking forward to testing ONP-002 to help determine if it can improve patient outcomes.
• Michael Redmond, President of Oragenics, stated that they are fortunate to have such an esteemed emergency medicine physician and researcher join their team and believes Dr. Peacock will play an invaluable role in the success of Oragenics and planned Phase II trials.

Industry Context

The appointment of a Chief Clinical Officer with Dr. Peacock's experience highlights the growing focus on developing effective treatments for concussions and other neurological disorders. The use of intranasal delivery and blood biomarkers is also a trend in the industry.

Comparison to Industry Standards

• The development of intranasal treatments for neurological conditions is an area of active research, with companies like Impel NeuroPharma also exploring this delivery method.
• The use of blood biomarkers to assess concussion severity is being investigated by companies such as Abbott and Quanterix, making Dr. Peacock's experience in this area highly relevant.
• The Phase II trial for ONP-002 will be compared to other concussion treatment trials, such as those conducted by companies like Biohaven Pharmaceuticals, to assess its efficacy.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of Dr. Peacock and the progression to Phase II trials as positive developments.
• Employees may be motivated by the company's progress and the addition of a respected leader.
• Patients with concussions may benefit from the development of a new treatment option.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• Oragenics will proceed with the Phase II clinical trial for ONP-002.
• The company will continue to work with Avance Clinical for the trial.
• The company will analyze the data from the Phase II trial to determine the effectiveness of ONP-002.

Key Dates

Keywords

concussion, ONP-002, clinical trial, intranasal, neurology, biomarkers, emergency medicine, Phase II, mTBI, Oragenics